Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Myeloproliferative Disorders 3Lymphoma 3Primary Myelofibrosis 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 52Cyclophosphamide 49Lenalidomide 40fludarabine 24obinutuzumab 22Prednisone 18Magnetic Resonance Spectroscopy 18Bendamustine Hydrochloride 18Vincristine 16fludarabine phosphate 15Specimen Handling 15Doxorubicin 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tisagenlecleucel 4tafasitamab 4polatuzumab vedotin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × parsaclisib × 1 year × Clear all
NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Incyte Corporation

Phase 1 Completed
26 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Incyte Corporation

Phase 1 Completed
50 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡